III期研究-话题@MedSci

#III期研究#

101篇内容 | 2920人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2021353, encodeId=20602021353c6, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=2019 ESMO：Arfolitixorin治疗转移性结直肠癌的全球III期研究, objectType=article, longId=180370, objectId=a2be1803e048, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a2be1803e048, replyNumber=0, likeNumber=72, createdTime=2020-03-02, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a2be1803e048, moduleTitle=2019 ESMO：Arfolitixorin治疗转移性结直肠癌的全球III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a2be1803e048)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021352, encodeId=84d82021352bf, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=abexinostat治疗肾癌的III期研究：首位中国患者已经入组, objectType=article, longId=179479, objectId=787e1e9479e7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=787e1e9479e7, replyNumber=0, likeNumber=59, createdTime=2019-09-26, rootId=0, userName=zhaojie88, userId=4c37265, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=787e1e9479e7, moduleTitle=abexinostat治疗肾癌的III期研究：首位中国患者已经入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=787e1e9479e7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021344, encodeId=f8cd2021344f9, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点, objectType=article, longId=161873, objectId=c2ee1618e324, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2ee1618e324, replyNumber=0, likeNumber=73, createdTime=2019-12-11, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2ee1618e324, moduleTitle=抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2ee1618e324)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021349, encodeId=551f2021349d2, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Mallinckrodt的特利加压素达到1型肝肾综合症III期研究的主要目标, objectType=article, longId=177803, objectId=fbaf1e78035c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fbaf1e78035c, replyNumber=0, likeNumber=59, createdTime=2020-04-08, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fbaf1e78035c, moduleTitle=Mallinckrodt的特利加压素达到1型肝肾综合症III期研究的主要目标, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fbaf1e78035c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021341, encodeId=8003202134156, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Theravance Biopharma宣布Ampreloxetine III期研究治疗症状性神经源性直立性低血压患者入组, objectType=article, longId=159219, objectId=850a159219d1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=850a159219d1, replyNumber=0, likeNumber=0, createdTime=2019-02-26, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=850a159219d1, moduleTitle=Theravance Biopharma宣布Ampreloxetine III期研究治疗症状性神经源性直立性低血压患者入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=850a159219d1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021340, encodeId=f2f220213403e, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Vertex制药表示VX-659三联疗法治疗囊肿性纤维化的III期研究达到了主要终点, objectType=article, longId=154586, objectId=9b231545869e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b231545869e, replyNumber=0, likeNumber=60, createdTime=2019-07-16, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b231545869e, moduleTitle=Vertex制药表示VX-659三联疗法治疗囊肿性纤维化的III期研究达到了主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b231545869e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021345, encodeId=15f7202134574, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=早产儿坏死性小肠结肠炎：IBT和FDA就III期研究的设计达成一致, objectType=article, longId=166544, objectId=2a63166544a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a63166544a6, replyNumber=0, likeNumber=81, createdTime=2020-02-25, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a63166544a6, moduleTitle=早产儿坏死性小肠结肠炎：IBT和FDA就III期研究的设计达成一致, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a63166544a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021342, encodeId=ee76202134261, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=胰腺癌治疗Lynparza在胰腺癌III期研究中达到了主要目标 , objectType=article, longId=161221, objectId=c211161221c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c211161221c7, replyNumber=0, likeNumber=68, createdTime=2019-09-23, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c211161221c7, moduleTitle=胰腺癌治疗Lynparza在胰腺癌III期研究中达到了主要目标 , moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c211161221c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021343, encodeId=ce222021343cb, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Vertex的VX-445三联组合方案治疗囊性纤维化的III期研究达到主要终点, objectType=article, longId=161868, objectId=3a6b1618681b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3a6b1618681b, replyNumber=0, likeNumber=65, createdTime=2019-09-29, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3a6b1618681b, moduleTitle=Vertex的VX-445三联组合方案治疗囊性纤维化的III期研究达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3a6b1618681b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021336, encodeId=28db2021336b6, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活, objectType=article, longId=136871, objectId=94111368e1b3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=94111368e1b3, replyNumber=0, likeNumber=91, createdTime=2019-01-12, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=94111368e1b3, moduleTitle=比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=94111368e1b3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021338, encodeId=b242202133857, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=大冢制药的guadecitabine未达到一线治疗AML的III期研究的主要终点, objectType=article, longId=145679, objectId=d3dd1456e979, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3dd1456e979, replyNumber=0, likeNumber=65, createdTime=2019-05-10, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3dd1456e979, moduleTitle=大冢制药的guadecitabine未达到一线治疗AML的III期研究的主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3dd1456e979)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021337, encodeId=6dfb202133e02, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Journal of Clinical Gastroenterology：鳞状细胞癌抗原血清测定可以作为Barrett食管和食管癌的生物标记物：III期研究, objectType=article, longId=139693, objectId=10331396935d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10331396935d, replyNumber=0, likeNumber=71, createdTime=2018-08-21, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10331396935d, moduleTitle=Journal of Clinical Gastroenterology：鳞状细胞癌抗原血清测定可以作为Barrett食管和食管癌的生物标记物：III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10331396935d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021339, encodeId=a162202133968, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=OPKO公司完成生长激素缺乏患儿（hGH-CTP）的Somatrogon全球III期研究的入组, objectType=article, longId=145945, objectId=022514594548, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=022514594548, replyNumber=0, likeNumber=64, createdTime=2018-09-27, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=022514594548, moduleTitle=OPKO公司完成生长激素缺乏患儿（hGH-CTP）的Somatrogon全球III期研究的入组, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=022514594548)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021333, encodeId=9ca62021333f3, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Lancet：【重磅】III期研究显示肝癌治疗新药仑伐替尼有望成为一线治疗晚期肝癌标准, objectType=article, longId=129750, objectId=01d9129e5085, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=01d9129e5085, replyNumber=0, likeNumber=66, createdTime=2018-07-12, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=01d9129e5085, moduleTitle=Lancet：【重磅】III期研究显示肝癌治疗新药仑伐替尼有望成为一线治疗晚期肝癌标准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=01d9129e5085)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021335, encodeId=67712021335ff, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=安罗替尼III期研究ALTER0303数据写入《2018版CSCO肺癌指南》, objectType=article, longId=136178, objectId=a6311361e8bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a6311361e8bb, replyNumber=0, likeNumber=68, createdTime=2019-02-17, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a6311361e8bb, moduleTitle=安罗替尼III期研究ALTER0303数据写入《2018版CSCO肺癌指南》, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a6311361e8bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021334, encodeId=0e97202133428, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Arthritis Rheumatol：阿巴西普治疗多关节型幼年特发性关节炎的III期研究, objectType=article, longId=131452, objectId=61ff131452ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61ff131452ed, replyNumber=0, likeNumber=87, createdTime=2018-10-06, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61ff131452ed, moduleTitle=Arthritis Rheumatol：阿巴西普治疗多关节型幼年特发性关节炎的III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61ff131452ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021332, encodeId=be902021332fb, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Ann Rheum Dis： LBEC0101和依那西普对甲氨蝶呤反应不良性活动类风湿关节炎患者疗效和安全性的III期研究, objectType=article, longId=124092, objectId=25b012409255, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b012409255, replyNumber=0, likeNumber=64, createdTime=2018-01-09, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b012409255, moduleTitle=Ann Rheum Dis： LBEC0101和依那西普对甲氨蝶呤反应不良性活动类风湿关节炎患者疗效和安全性的III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25b012409255)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021331, encodeId=7170202133185, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=葛兰素史克启动IL-5抗炎药Nucala治疗重度嗜酸性粒细胞增多综合征（HES）关键III期研究, objectType=article, longId=96292, objectId=60ba962924a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60ba962924a, replyNumber=0, likeNumber=0, createdTime=2017-09-03, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60ba962924a, moduleTitle=葛兰素史克启动IL-5抗炎药Nucala治疗重度嗜酸性粒细胞增多综合征（HES）关键III期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60ba962924a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021330, encodeId=843a202133029, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=Auris Medical治疗耳鸣新药Keyzilen临床III期研究宣告失败, objectType=article, longId=75644, objectId=662be564402, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=662be564402, replyNumber=0, likeNumber=72, createdTime=2016-12-04, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=662be564402, moduleTitle=Auris Medical治疗耳鸣新药Keyzilen临床III期研究宣告失败, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=662be564402)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=2021328, encodeId=62112021328ad, content=<a href='/topic/show?id=69d595e421' target=_blank style='color:#2F92EE;'>#III期研究#</a>, objectTitle=进新一代降脂药PCSK9抑制剂Repatha治疗他汀不耐受高胆固醇血症III期研究获得成功, objectType=article, longId=63537, objectId=661e6353e48, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=661e6353e48, replyNumber=0, likeNumber=62, createdTime=2016-09-09, rootId=0, userName=HinsMax, userId=910c2500152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=661e6353e48, moduleTitle=进新一代降脂药PCSK9抑制剂Repatha治疗他汀不耐受高胆固醇血症III期研究获得成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=661e6353e48)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

III期研究

2020-05-29

zhaojie88 (审核中...)

前往app查看评论内容

#III期研究#

2019 ESMO：Arfolitixorin治疗转移性结直肠癌的全球III期研究

2020-03-02

zhaojie88 (审核中...)

前往app查看评论内容

#III期研究#

abexinostat治疗肾癌的III期研究：首位中国患者已经入组

2019-09-26

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

抗抑郁新药rapastinel遭遇挫折：未达到III期研究的主要终点

2019-12-11

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Mallinckrodt的特利加压素达到1型肝肾综合症III期研究的主要目标

2020-04-08

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Theravance Biopharma宣布Ampreloxetine III期研究治疗症状性神经源性直立性低血压患者入组

2019-02-26

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Vertex制药表示VX-659三联疗法治疗囊肿性纤维化的III期研究达到了主要终点

2019-07-16

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

早产儿坏死性小肠结肠炎：IBT和FDA就III期研究的设计达成一致

2020-02-25

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

胰腺癌治疗Lynparza在胰腺癌III期研究中达到了主要目标 

2019-09-23

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Vertex的VX-445三联组合方案治疗囊性纤维化的III期研究达到主要终点

2019-09-29

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

比较SB3（曲妥珠单抗生物仿制药）和曲妥珠单抗治疗HER2阳性早期乳腺癌的III期研究：最终安全性，免疫原性和存活

2019-01-12

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

大冢制药的guadecitabine未达到一线治疗AML的III期研究的主要终点

2019-05-10

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Journal of Clinical Gastroenterology：鳞状细胞癌抗原血清测定可以作为Barrett食管和食管癌的生物标记物：III期研究

2018-08-21

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

OPKO公司完成生长激素缺乏患儿（hGH-CTP）的Somatrogon全球III期研究的入组

2018-09-27

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Lancet：【重磅】III期研究显示肝癌治疗新药仑伐替尼有望成为一线治疗晚期肝癌标准

2018-07-12

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

安罗替尼III期研究ALTER0303数据写入《2018版CSCO肺癌指南》

2019-02-17

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Arthritis Rheumatol：阿巴西普治疗多关节型幼年特发性关节炎的III期研究

2018-10-06

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Ann Rheum Dis： LBEC0101和依那西普对甲氨蝶呤反应不良性活动类风湿关节炎患者疗效和安全性的III期研究

2018-01-09

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

葛兰素史克启动IL-5抗炎药Nucala治疗重度嗜酸性粒细胞增多综合征（HES）关键III期研究

2017-09-03

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

Auris Medical治疗耳鸣新药Keyzilen临床III期研究宣告失败

2016-12-04

HinsMax (审核中...)

前往app查看评论内容

#III期研究#

进新一代降脂药PCSK9抑制剂Repatha治疗他汀不耐受高胆固醇血症III期研究获得成功

2016-09-09

科室
- - 订阅+
  - 更多科室
工具
服务